Uptake of 18F-rhPSMA-7.3 in Positron Emission Tomography Imaging of Prostate Cancer: A Phase 1 Proof-of-Concept Study-Reference-Cited by-同舟云学术

Uptake of 18F-rhPSMA-7.3 in Positron Emission Tomography Imaging of Prostate Cancer: A Phase 1 Proof-of-Concept Study

Published:2021-12-28 Issue: Volume: Page:
ISSN:1084-9785
Container-title:Cancer Biotherapy and Radiopharmaceuticals
language:en
Short-container-title:Cancer Biotherapy and Radiopharmaceuticals

Author:

Malaspina Simona¹^ORCID,Taimen Pekka²,Kallajoki Markku²,Oikonen Vesa¹,Kuisma Anna³,Ettala Otto⁴,Mattila Kalle³,Boström Peter J.⁴,Minn Heikki³^ORCID,Kalliokoski Kari¹,Postema Ernst J.⁵,Miller Matthew P.⁵,Scheinin Mika²⁶

Affiliation:

1. Turku PET Centre, University of Turku and Turku University Hospital, Turku, Finland.

2. Institute of Biomedicine and FICAN West Cancer Center, University of Turku and Department of Pathology, Turku University Hospital, Turku, Finland.

3. Department of Oncology and University of Turku and Turku University Hospital, Turku, Finland.

4. Department of Urology, University of Turku and Turku University Hospital, Turku, Finland.

5. Blue Earth Diagnostics Ltd., Oxford, United Kingdom.

6. Clinical Research Services Turku–CRST Ltd., Turku, Finland.

Publisher

Mary Ann Liebert Inc

Subject

Cancer Research,Pharmacology,Radiology, Nuclear Medicine and imaging,Oncology,General Medicine,Cancer Research,Pharmacology,Radiology, Nuclear Medicine and imaging,Oncology,General Medicine

Link

https://www.liebertpub.com/doi/pdf/10.1089/cbr.2021.0322

Reference21 articles.

1. Prostate-Specific Membrane Antigen-Targeted Radiopharmaceuticals in Diagnosis and Therapy of Prostate Cancer: Current Status and Future Perspectives

2. Preclinical comparison of four [18F, natGa]rhPSMA-7 isomers: influence of the stereoconfiguration on pharmacokinetics

3. Radiohybrid Ligands: A Novel Tracer Concept Exemplified by 18F- or 68Ga-Labeled rhPSMA Inhibitors

4. Safety, Biodistribution, and Radiation Dosimetry of 18F-rhPSMA-7.3 in Healthy Adult Volunteers

5. Kinetic analysis and optimisation of 18F-rhPSMA-7.3 PET imaging of prostate cancer

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Prostate-specific Membrane Antigen;PET Clinics;2024-07

2. True-Positive¹⁸F-Flotufolastat Lesions in Patients with Prostate Cancer Recurrence with Baseline-Negative Conventional Imaging: Results from the Prospective, Phase 3, Multicenter SPOTLIGHT Study;Journal of Nuclear Medicine;2024-05-23

3. Diagnostic Performance and Safety of Positron Emission Tomography with 18F-rhPSMA-7.3 in Patients with Newly Diagnosed Unfavourable Intermediate- to Very-high-risk Prostate Cancer: Results from a Phase 3, Prospective, Multicentre Study (LIGHTHOUSE);European Urology;2023-10

4. Application of targeted diagnosis of PSMA in the modality shift of prostate cancer diagnosis: a review;Frontiers in Oncology;2023-09-01

5. Diagnostic Performance and Safety of ¹⁸ F-rhPSMA-7.3 Positron Emission Tomography in Men With Suspected Prostate Cancer Recurrence: Results From a Phase 3, Prospective, Multicenter Study (SPOTLIGHT);Journal of Urology;2023-08